Amsbio is adding experimental cell lines to its CAR-T cell services to meet an increasing demand for the technology, according to the UK-based provider.
CrownBio’s new stable cell lines feature various immune checkpoints and receptors which are key targets and pathways for oncology drug discovery and development.
Abenza subsidiary Antitope has extended its relationship and will provide manufacturing cell lines for two developing HIV vaccines from the French National Institute of Health and Medical Research (INSERM); the National Health Agency for Research on AIDS...
Horizon says its £6m (€7.7m) purchase of Austrian biotech Haplogen Genomics means it can produce cell lines ten times faster than before using a haploid gene platform.
Horizon, which supplies genomics research services, has bought cell-screening business CombinatoRx from Zalicus for £4.74m ($8m) and plans more acquisitions.
Artelis president Jose Castilo believes that the record MAb yield from CHO cells grown in its iCELLis bioreactor shows the platform could shift the paradigm for the "production of recombinant proteins.”
Sangamo Biosciences and Sigma-Aldrich have licensed their zinc
finger nuclease (ZFN) technology to Roche to enable the pharma
giant to develop cell lines and transgenic animals.
US firms Multispan and Promega have paired up to develop assay
tools for G-protein coupled receptor (GPCR) screening, in the hope
of speeding up drug discovery on these, the most popular protein
targets in pharma.
Sigma-Aldrich has launched a new technology that promises to
dramatically simplify and speed-up high-throughput (HT) RNAi
screening of the human kinome.
Cardinal Health says it is experiencing a "robust market" for its
cell line engineering technology, as it attracts the attention of
pharma giant Wyeth and executes capacity expansion plans its for
full service offerings...
Tapestry has presented data that supports the oral bioavailability
and antitumour activity of its drug candidate designed to overcome
multi-drug resistance in solid tumours that have become resistant
to taxane therapy.
Centocor has enlisted Cardinal Health to use its rapid cell line
development technology to engineer cell lines expressing Centocor's
monoclonal antibodies, and speed up the development of new
biopharmaceuticals.
Chromos Molecular Systems won another customer for its cell line
engineering technology yesterday, when world number one drugmaker
Pfizer took out a license for its ACE system, reports Phil
Taylor.
Applying automation to tissue culture techniques can improve the
development, maintenance and expansion of mammalian cells,
increasing the efficiency of drug discovery efforts, reports Wai
Lang Chu.
